Moderna, Inc. (MRNA) stock experienced a significant pre-market decline of 5.1% following an analyst price target revision. The pre-market plunge occurred on Thursday, March 6th, 2025.
According to reports, Berenberg analysts adjusted their price target for Moderna down to $30 from the previous target of $33. The analysts maintained their "Hold" rating on the stock, reflecting a cautious outlook.
The downward revision of the price target by Berenberg analysts appears to have contributed to the pre-market sell-off in Moderna's shares. Investors reacted negatively to the reduced price expectations, as reflected in the stock's 5.1% drop during the pre-market trading session.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。